The early revenue generation and rapid payer adoption of KOMZIFTI suggest strong commercial viability. With multiple clinical data readouts expected in 2026 and a well-funded runway into 2028, traders should monitor upcoming data from KOMET-007 (1H 2026) and the progression of Phase 3 frontline trials as key value inflection points.
KURA drugs
KURA drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 5 $8.51entry
- T+1 · 9mo ago +5.29%α +6.60% · $8.96
- T+5 · 8mo ago +3.88%α +6.12% · $8.84
- T+20 · 8mo ago +1.18%α +4.96% · $8.61
- T+60 · 6mo ago +6.17%α −5.13% · $9.04
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kura Oncology reported Q4 and full-year 2025 financial results, highlighted by $2.1 million in net product revenue from the initial five weeks of KOMZIFTI™ (ziftomenib) commercial sales following its November 13 FDA approval for R/R NPM1-mutated AML. The company emphasized strong early commercial momentum, rapid payer coverage, and a robust cash position of $667.2 million, which, combined with $180 million in anticipated collaboration payments, is expected to fund operations into Q4 2027 and advance ziftomenib to Phase 3 topline data in frontline AML by 2028.
Key Financial Metrics
Key Facts
- Generated $2.1 million in net product revenue from KOMZIFTI in first five weeks post-FDA approval (Nov 13–Dec 31, 2025)
- Received $135 million milestone payment from Kyowa Kirin upon product delivery within five days of approval
- Cash, cash equivalents, and short-term investments totaled $667.2 million as of December 31, 2025
- Anticipated $180 million in future collaboration payments from Kyowa Kirin to support development through Phase 3 AML data
- Net loss widened to $81.0 million in Q4 2025 vs. $19.2 million in Q4 2024 due to increased R&D and SG&A expenses tied to commercialization
- Initiated pivotal Phase 3 KOMET-017 trials in frontline AML, triggering two $30 million milestone payments from Kyowa Kirin
Financial Impact
$2.1 million in net product revenue in first partial quarter; $15.2 million collaboration revenue in Q4; total cash resources (~$847M with expected milestones) sufficient to fund through key 2028 Phase 3 readout
Risk Factors
- Differentiation syndrome observed in 26% of patients, including fatal cases, which may limit use or require risk mitigation
- Widening net loss ($81M in Q4) driven by rising R&D and commercialization costs
- Future collaboration payments from Kyowa Kirin are contingent on milestones and not guaranteed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249967 |
Track record
29 reports on KURA
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 9 of 13 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers